A Phase 1 interventional study of LY3502970 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 5 sites in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 1, and was the 3rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in India, Saudi Arabia, South Africa and 1 more country
Ages 18–65
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 8 more countries
Ages 10–17
Massachusetts General Hospital
Ages 18–79
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 2 started in 2021.
This study's enrollment of 62 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 546 across the 15 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 168th largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2021, is one of 76 in phase 1, and was the 178th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing orforglipron in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613307Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | 2027-05 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single doses of LY3502970 administered orally.
Drug: LY3502970
Participants received multiple doses of LY3502970 administered orally.
Drug: LY3502970
Participants received placebo administered orally.
Drug: Placebo
Participants received placebo administered orally.
Drug: Placebo
Administered orally
Administered orally
Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Baseline Through Follow-Up (Up To Week 15)
Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3502970 on Day 1
PK: Cmax of LY3502970.
Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)
Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1
PK: AUC\[0-tlast\] of LY3502970.
Time frame: Day 1 (Pre-dose, 0.5, 1, 2, 4, 8, 12, 16, 24, 48, 72 and 96 hours post-dose)
Part B: PK: Cmax of LY3502970 on Day 84
PK: Cmax of LY3502970.
Time frame: Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)
Part B: PK: AUC[0-tlast] of LY3502970 on Day 84
PK: AUC\[0-tlast\] of LY3502970.
Time frame: Day 84 (Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 96 and 336 hours post-dose)
Change From Baseline in Fasting Glucose
Change from Baseline in Fasting Glucose was reported. Least square mean was calculated using the model: Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\*Timepoint + Participant + Random Error, where participant was fitted as a random effect.
Time frame: Baseline through Day 85
Change From Baseline in Glycated Hemoglobin (HbA1c)
Change from Baseline in HbA1c. Least square mean was calculated using model Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\*Timepoint + Participant + Random Error, where participant is fitted as a random effect
Time frame: Baseline through Day 85
Change From Baseline in Body Weight
Change from Baseline in Body Weight. Least square mean was calculated using Model: Change from baseline = Baseline + Treatment + Time + Treatment\*Time + participant + Random Error, where participant was fitted as a random effect
Time frame: Baseline through Day 88
A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
| Milestone | Cohort 1a - Placebo | Cohort 1a - LY3502970 | Cohort 2a - Placebo | Cohort 2a - LY3502970 | Cohort 1b - Placebo QD | Cohort 1b - LY3502970 QD | Cohort 2b - Placebo QD | Cohort 2b - LY3502970 QD | Cohort 3a - Placebo QD | Cohort 3a - LY3502970 QD | Cohort 3b - Placebo QD | Cohort 3b - LY3502970 QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 10 | 2 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least one dose of study drug | 2 | 10 | 2 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 8 | 2 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Cohort 1a - Placebo | Cohort 1a - LY3502970 | Cohort 2a - Placebo | Cohort 2a - LY3502970 | Cohort 1b - Placebo QD | Cohort 1b - LY3502970 QD | Cohort 2b - Placebo QD | Cohort 2b - LY3502970 QD | Cohort 3a - Placebo QD | Cohort 3a - LY3502970 QD | Cohort 3b - Placebo QD | Cohort 3b - LY3502970 QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 10 | 2 | 9 | 1 | 7 | 2 | 9 | 2 | 7 | 2 | 7 |
| Received at least one dose of study drug | 2 | 10 | 2 | 9 | 1 | 7 | 2 | 9 | 2 | 7 | 2 | 7 |
| Completed | 1 | 9 | 2 | 9 | 1 | 5 | 2 | 8 | 2 | 6 | 2 | 7 |
| Not completed | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
A TEAE is an untoward medical occurrence that emerges during a defined treatment period, having been absent pretreatment, or worsens relative to the pretreatment state, and does not necessarily have to have a causal relationship with this treatment. An SAE is any adverse event from this study that results in 1 of the following: Death, initial or prolonged inpatient hospitalization, a life-threatening experience, persistent or significant disability/incapacity, congenital anomaly/birth defect, important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above. An overall summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
| Participants | Placebo - Part A | 2 mg LY3502970 - Part A | 3 mg LY3502970 - Part A | Placebo QD - Part B | 2(or 3)/3/6/12 mg LY3502970 QD - Part B | 2/3/6/8/12/24 mg LY3502970 QD - Part B | 2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B |
|---|---|---|---|---|---|---|---|
| TEAEs | 2 | 5 | 5 | 4 | 11 | 12 | 9 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PK: Cmax of LY3502970.
| nanograms per milliliter (ng/mL) | 2 mg LY3502970 - Part A | 3 mg LY3502970 - Part A |
|---|---|---|
| Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3502970 on Day 1 | 9.70 ± 34 | 18.1 ± 38 |
PK: AUC\[0-tlast\] of LY3502970.
| nanogram hour per milliliter (ng*h/mL) | 2 mg LY3502970 - Part A | 3 mg LY3502970 - Part A |
|---|---|---|
| Part A: PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1 | 236 ± 30 | 412 ± 29 |
PK: Cmax of LY3502970.
| nanograms per milliliter (ng/mL) | 12 mg LY3502970 - Part B | 24 mg LY3502970 - Part B | 45 mg LY3502970 - Part B |
|---|---|---|---|
| Part B: PK: Cmax of LY3502970 on Day 84 | 112 ± 37 | 139 ± 42 | 279 ± 53 |
PK: AUC\[0-tlast\] of LY3502970.
| nanogram hour per milliliter (ng*h/mL) | 12 mg LY3502970 - Part B | 24 mg LY3502970 - Part B | 45 mg LY3502970 - Part B |
|---|---|---|---|
| Part B: PK: AUC[0-tlast] of LY3502970 on Day 84 | 5860 ± 68 | 7480 ± 83 | 11200 ± 80 |
Change from Baseline in Fasting Glucose was reported. Least square mean was calculated using the model: Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\*Timepoint + Participant + Random Error, where participant was fitted as a random effect.
| milligrams per deciliter (mg/dL) | Placebo QD - Part B | 2(or 3)/3/6/12 mg LY3502970 QD - Part B | 2/3/6/8/12/24 mg LY3502970 QD - Part B | 2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B |
|---|---|---|---|---|
| Change From Baseline in Fasting Glucose | 7.40 (-4.08 to 18.89) | -64.82 (-71.18 to -58.46) | -61.08 (-67.12 to -55.03) | -65.56 (-70.91 to -60.22) |
Change from Baseline in HbA1c. Least square mean was calculated using model Log(Parameter) - Log(Baseline) = Log(Baseline) + Treatment + Timepoint + Treatment\*Timepoint + Participant + Random Error, where participant is fitted as a random effect
| Percentage of HbA1c | Placebo QD - Part B | 2(or 3)/3/6/12 mg LY3502970 QD - Part B | 2/3/6/8/12/24 mg LY3502970 QD - Part B | 2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B |
|---|---|---|---|---|
| Change From Baseline in Glycated Hemoglobin (HbA1c) | 0.67 (0.20 to 1.14) | -2.16 (-2.45 to -1.87) | -2.17 (-2.44 to -1.91) | -2.28 (-2.52 to -2.04) |
Change from Baseline in Body Weight. Least square mean was calculated using Model: Change from baseline = Baseline + Treatment + Time + Treatment\*Time + participant + Random Error, where participant was fitted as a random effect
| kilogram (kg) | Placebo QD - Part B | 2(or 3)/3/6/12 mg LY3502970 QD - Part B | 2/3/6/8/12/24 mg LY3502970 QD - Part B | 2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B |
|---|---|---|---|---|
| Change From Baseline in Body Weight | -0.5 (-2.3 to 1.3) | -3.4 (-5.0 to -1.7) | -6.9 (-8.4 to -5.4) | -4.9 (-6.3 to -3.5) |
Collected over Baseline Through Follow-Up (Up To Week 15). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Part A | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| 2 mg LY3502970 - Part A | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| 3 mg LY3502970 - Part A | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Placebo QD - Part B | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| 2(or 3)/3/6/12 mg LY3502970 QD - Part B | 0/14 (0%) | 0/14 (0%) | 11/14 (78.6%) |
| 2/3/6/8/12/24 mg LY3502970 QD - Part B | 0/17 (0%) | 0/17 (0%) | 13/17 (76.5%) |
| 2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B | 0/18 (0%) | 0/18 (0%) | 9/18 (50%) |
| Event | Placebo - Part A | 2 mg LY3502970 - Part A | 3 mg LY3502970 - Part A | Placebo QD - Part B | 2(or 3)/3/6/12 mg LY3502970 QD - Part B | 2/3/6/8/12/24 mg LY3502970 QD - Part B | 2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/4 | 3/10 | 5/9 | 2/11 | 9/14 | 4/17 | 6/18 |
| VomitingGastrointestinal disorders | 1/4 | 4/10 | 2/9 | 1/11 | 3/14 | 2/17 | 1/18 |
| Decreased appetiteMetabolism and nutrition disorders | 0/4 | 1/10 | 0/9 | 1/11 | 5/14 | 3/17 | 3/18 |
| ConstipationGastrointestinal disorders | 0/4 | 0/10 | 3/9 | 1/11 | 2/14 | 3/17 | 5/18 |
| Abdominal discomfortGastrointestinal disorders | 1/4 | 1/10 | 0/9 | 0/11 | 1/14 | 3/17 | 0/18 |
| HeadacheNervous system disorders | 1/4 | 0/10 | 1/9 | 1/11 | 3/14 | 0/17 | 2/18 |
| Abdominal distensionGastrointestinal disorders | 0/4 | 2/10 | 0/9 | 0/11 | 1/14 | 1/17 | 0/18 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/10 | 0/9 | 2/11 | 1/14 | 2/17 | 0/18 |
| EructationGastrointestinal disorders | 0/4 | 0/10 | 0/9 | 0/11 | 2/14 | 0/17 | 1/18 |
| Head discomfortNervous system disorders | 0/4 | 0/10 | 0/9 | 0/11 | 2/14 | 0/17 | 0/18 |
All participants who were enrolled in Part A, Part B. A total of 62 participants were enrolled in the trial. Part A consisted of 23 participants of which 21 completed. Part B consisted of 60 participants inclusive of the 21 completers from Part A as per the Protocol.
| Age, Continuous(years) | Placebo - Part A | 2 mg LY3502970 - Part A | 3 mg LY3502970 - Part A | Placebo QD - Part B | 3/6/12 mg LY3502970 QD - Part B | 2/3/6/12 mg LY3502970 QD - Part B | 2/3/6/8/12/24 mg LY3502970 QD - Part B | 3/6/12/24/36/45 mg LY3502970 QD - Part B | 2/3/6/12/24/36/45 mg LY3502970 QD - Part B | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Part A | 55.5 ± 1.7 | 53.1 ± 11.7 | 57.6 ± 5.5 | — | — | — | — | — | — | 55.3 ± 8.5 |
| Part B | — | — | — | 57.7 ± 5.8 | 58.0 ± 6.8 | 56.3 ± 8.6 | 53.4 ± 10.0 | 57.6 ± 5.5 | 57.7 ± 7.1 | 56.1 ± 8 |
| Sex: Female, Male(Participants) | Placebo - Part A | 2 mg LY3502970 - Part A | 3 mg LY3502970 - Part A | Placebo QD - Part B | 3/6/12 mg LY3502970 QD - Part B | 2/3/6/12 mg LY3502970 QD - Part B | 2/3/6/8/12/24 mg LY3502970 QD - Part B | 3/6/12/24/36/45 mg LY3502970 QD - Part B | 2/3/6/12/24/36/45 mg LY3502970 QD - Part B | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Part A — Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A — Male | 4 | 10 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 23 |
| Part B — Female | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 |
| Part B — Male | 0 | 0 | 0 | 10 | 6 | 7 | 17 | 9 | 9 | 58 |
| Race (NIH/OMB)(Participants) | Placebo - Part A | 2 mg LY3502970 - Part A | 3 mg LY3502970 - Part A | Placebo QD - Part B | 3/6/12 mg LY3502970 QD - Part B | 2/3/6/12 mg LY3502970 QD - Part B | 2/3/6/8/12/24 mg LY3502970 QD - Part B | 3/6/12/24/36/45 mg LY3502970 QD - Part B | 2/3/6/12/24/36/45 mg LY3502970 QD - Part B | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Part A — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A — Asian | 4 | 10 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 23 |
| Part A — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A — White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A — More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part A — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part B — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part B — Asian | 0 | 0 | 0 | 11 | 7 | 7 | 17 | 9 | 9 | 60 |
| Part B — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part B — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part B — White | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part B — More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part B — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo - Part A | 2 mg LY3502970 - Part A | 3 mg LY3502970 - Part A | Placebo QD - Part B | 3/6/12 mg LY3502970 QD - Part B | 2/3/6/12 mg LY3502970 QD - Part B | 2/3/6/8/12/24 mg LY3502970 QD - Part B | 3/6/12/24/36/45 mg LY3502970 QD - Part B | 2/3/6/12/24/36/45 mg LY3502970 QD - Part B | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Japan | 4 | 10 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 23 |
| Region of Enrollment(Participants) | Placebo - Part A | 2 mg LY3502970 - Part A | 3 mg LY3502970 - Part A | Placebo QD - Part B | 3/6/12 mg LY3502970 QD - Part B | 2/3/6/12 mg LY3502970 QD - Part B | 2/3/6/8/12/24 mg LY3502970 QD - Part B | 3/6/12/24/36/45 mg LY3502970 QD - Part B | 2/3/6/12/24/36/45 mg LY3502970 QD - Part B | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Japan | 0 | 0 | 0 | 11 | 7 | 7 | 17 | 9 | 9 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Sep 2022, 9 months.
Results were first posted in Jul 2026, 3 years 10 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 9 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron